Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

Survival rates similar when treating secondary MR with TEER or surgery

Surgical mitral valve repair, however, was also associated with multiple benefits.

Thumbnail

Why 'leaky' heart valves in pregnant women should not be ignored

The new analysis, published in the American Journal of Cardiology, explored the increased risk of adverse obstetric and cardiovascular events among pregnant women.

Thumbnail

3 conditions associated with a higher stroke risk among TAVR patients

The new analysis, published in Current Problems in Cardiology, also explored the higher costs associated with post-TAVR stroke. 

Amulet vs. Watchman: LAA occluder devices compared in new head-to-head trial

The Amulet's implantation success rate and LAA closure rate were both higher than the first-generation Watchman device, researchers reported.

Thumbnail

Echocardiography-guided LAAC boosts patient outcomes

LAAC patients see clear benefits when echocardiographic guidance (EG) is used in addition to fluoroscopy.

New meta-analysis examines valve durability after 5 years among TAVR, SAVR patients

As TAVR and SAVR patients get younger, valve durability will continue to gain more and more importance.

Thumbnail

Edoxaban comparable to VKAs for treating AFib after TAVR

Researchers shared their findings at ESC Congress 2021 and in the New England Journal of Medicine

Thumbnail

Paravalvular leak after TAVR continues to be a problem—but advances in technology are helping

Additional studies are still necessary, but researchers are hopeful that modern TAVR solutions will help limit paravalvular leak in the years ahead. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.